Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 80 5-Year Yield-on-Cost % is 0.00 as of Jul. 16, 2026. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.05 (Fairly Valued). The stock has 1 warning sign investors should review. Among 280 Healthcare Providers & Services companies, Diaceutics ranks worse than 357142.5% on this metric.
Diaceutics's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Diaceutics's 5-Year Yield-on-Cost % or its related term are showing as below:
DIUXF's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.9 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Diaceutics 5-Year Yield-on-Cost % Related Terms
DIUXF vs VEEV, BTSG, TEM: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, Diaceutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Diaceutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Diaceutics is calculated as
Diaceutics (DIUXF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Diaceutics and its competitors. According to the industry distribution chart, Diaceutics ranks #999999 out of 280 companies in the Healthcare Providers & Services industry.
Is Diaceutics' 5-Year Yield-on-Cost % too high?
Diaceutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Diaceutics ranks #999999 out of 280 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #999999 out of 280 companies for 5-Year Yield-on-Cost %. This places Diaceutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 280 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.05, compared to a current price of $2.00 — trading 2.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Diaceutics (DIUXF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 2.4% below its estimated GF Value™ of $2.05.
GuruFocus considers Diaceutics to be Fairly Valued.
Key valuation signals for DIUXF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $2.05 vs. price of $2.00 (2.4% below fair value)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score
Get the complete analysis for DIUXF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
